跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

SML2228

Sigma-Aldrich

Fosaprepitant dimeglumine

≥98% (HPLC)

别名:

1-Deoxy-1(methylamino)-D-glucitol[3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonate (2:1) (salt), L-758,298, MK-0517, [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C23H22F7N4O6P · C14H34N2O10
CAS号:
265121-04-8
分子量:
1004.83
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D +27 to +34°, c = 0.5 in methanol

儲存條件

desiccated

顏色

white to beige

溶解度

H2O: 2 mg/mL, clear

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

FC1=CC=C([C@@H]2N(CCO[C@@H]2O[C@@H](C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C)CC(NC4=O)=NN4P(O)(O)=O)C=C1.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O

InChI

1S/C23H22F7N4O6P.2C7H17NO5/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38;2*1-8-2-4(10)6(12)7(13)5(11)3-9/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38);2*4-13H,2-3H2,1H3/t12-,19+,20-;2*4-,5+,6+,7+/m100/s1

InChI 密鑰

VRQHBYGYXDWZDL-OOZCZQCLSA-N

生化／生理作用

Fosaprepitant dimeglumine acts as a therapeutic agent to treat chemotherapy-induced nausea and vomiting. It also acts as a weak inhibitor of cytochrome P450 3A4 (CYP3A4).
Fosaprepitant dimeglumine is a Substance P/neurokinin-1 (NK1) receptor antagonist. It is a water soluble prodrug of the antiemetic drug aprepitant.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Priya Patel et al.
British journal of clinical pharmacology, 83(10), 2148-2162 (2017-05-05)
Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity. This systematic review evaluates clinically significant pharmacokinetic drug interactions with aprepitant and fosaprepitant and describes adverse events ascribed to drug interactions with aprepitant
Christina H Ruhlmann et al.
Expert review of anticancer therapy, 12(2), 139-150 (2012-02-10)
For patients receiving cancer chemotherapy, the ongoing development of antiemetic treatment is of significant importance. Patients consider nausea and vomiting among the most distressing symptoms of chemotherapy, and as new antiemetics have been very successful in prevention of vomiting, agents
Bernardo L Rapoport et al.
Future oncology (London, England), 14(1), 77-92 (2017-11-14)
Chemotherapy-induced nausea and vomiting (CINV) remains a challenge in cancer care. Improved understanding of CINV pathophysiology has triggered the development of new antiemetic therapeutic options, such as selective neurokinin-1 (NK1) receptor antagonists (RAs), which effectively prevent CINV when added to
Karly P Garnock-Jones
Drugs, 76(14), 1365-1372 (2016-08-12)
Intravenous fosaprepitant dimeglumine (Emend(®) for injection, IVEmend(®); henceforth referred to as fosaprepitant) is a prodrug of and is rapidly converted to the antiemetic aprepitant, and is approved in several countries worldwide (as part of an antiemetic regimen) for the prevention

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门